TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1973351

Group type: EXPERIMENTAL
Intervention: Social Skills Training (SST) - 25 twice a week 90-min group sessions
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Group Exposure (GE) - 4 weekly sessions (8-hr total, including 2 hr discussion)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Individual Exposure (IE) - 4 weekly sessions (3 hr total, including 1 hr discussion)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Group Exposure (GE) within skills deficits subgroup
Number of subjects: 78
Study: 41229

Group type: EXPERIMENTAL
Intervention: Tienilic acid 250 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 50 mg
Number of subjects: 0
Study: 30365247

Group type: EXPERIMENTAL
Intervention: Penimaster PRO group (PG)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Non-intervention group (NIG)
Number of subjects: 93
Study: 28812321

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily (Group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg daily (Group A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 26596056

Group type: EXPERIMENTAL
Intervention: Dabigatran (110 mg b.i.d)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg b.i.d)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg once daily)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 280
Study: 24002093

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Highest quintile of plasma tenofovir concentrations
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Highest quintile of intracellular tenofovir diphosphate concentration
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Higher plasma tenofovir concentrations
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Higher intracellular tenofovir diphosphate
Number of subjects: 203
Study: 20680696

Group type: EXPERIMENTAL
Intervention: Radiocolloid combined with methylene dye localization (RCML)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Wire localization (WL)
Number of subjects: 157
Study: 19747876

Group type: EXPERIMENTAL
Intervention: Dexamethasone-based protocol (DCOG ALL-9) for NHR patients: three-drug induction (dexamethasone, vincristine, asparaginase) for 6 weeks, medium-dose methotrexate for 3 weeks, maintenance therapy until 109 weeks.
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Dexamethasone-based protocol (DCOG ALL-9) for HR patients: four-drug induction (as for NHR plus daunorubicin) for 6 weeks, high-dose methotrexate for 8 weeks, maintenance therapy until 109 weeks.
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Overall results of the DCOG ALL-9 protocol for all patients.
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Overall results of the DCOG ALL-9 protocol for NHR patients.
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Overall results of the DCOG ALL-9 protocol for HR patients.
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Overall results of the DCOG ALL-9 protocol regarding isolated CNS relapses.
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Multivariate analysis of prognostic factors.
Number of subjects: 859
Study: 17978321

Group type: EXPERIMENTAL
Intervention: Multicomponent preventive intervention for disruptive boys
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 250
Study: 15530214

Group type: EXPERIMENTAL
Intervention: Parent Training (PT)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Waiting List Control (WLC)
Number of subjects: 89
Study: 11455770

Group type: EXPERIMENTAL
Intervention: 10 micrograms PGE1 + 15 mg papaverine hydrochloride + 0.5 mg phentolamine (trimix)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 30 mg papaverine hydrochloride + 1 mg phentolamine (bimix)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 20 micrograms PGE1
Number of subjects: 91
Study: 9926882

Group type: EXPERIMENTAL
Intervention: Joel-Cohen incision with nonclosure of pelvic and parietal peritoneum (group 1)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Pfannenstiel incision with peritonealization (group 2)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 299
Study: 7803722

Group type: EXPERIMENTAL
Intervention: AZT combined with poly(I):poly(C12U)
Number of subjects: 11

Group type: COMPARATOR
Intervention: AZT alone
Number of subjects: 11
Study: 3055036

Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg gadolinium diethylenetriaminepentaacetic acid (Gd‐DTPA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No Gd‐DTPA (control group)
Number of subjects: 20
Study: 29175149

Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine plus pertuzumab
Number of subjects: 444

Group type: COMPARATOR
Intervention: Docetaxel, carboplatin, and trastuzumab plus pertuzumab
Number of subjects: 444
Study: 28526536

Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (3·6 mg/kg intravenously every 3 weeks)
Number of subjects: 991

Group type: COMPARATOR
Intervention: Capecitabine (1000 mg/m2 orally twice daily on days 1‐14 of each 21-day cycle) plus Lapatinib (1250 mg orally once daily on days 1‐21)
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Number of subjects: 991

Group type: COMPARATOR
Intervention: Capecitabine plus Lapatinib (control)
Number of subjects: 991
Study: 26143520

Group type: EXPERIMENTAL
Intervention: Individualized video feedback (IVF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhanced unsupervised video feedback (UVF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard lecture feedback (SLF)
Number of subjects: 0
Study: 23250671

Group type: EXPERIMENTAL
Intervention: Angled-tipped guidewire (AGW)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Straight-tipped guidewire (SGW)
Number of subjects: 155
Study: 21990410

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg twice daily
Number of subjects: 561

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 561
Study: 18507579

Group type: EXPERIMENTAL
Intervention: Doula support during labor and delivery
Number of subjects: 420

Group type: COMPARATOR
Intervention: Control group (no doula support)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Doula support during induced labor
Number of subjects: 420

Group type: COMPARATOR
Intervention: Control group during induced labor
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Doula support overall experience
Number of subjects: 420
Study: 17040520

Group type: EXPERIMENTAL
Intervention: New facility policy on restraints (bedrails not to be used except under specified conditions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (routine use of bedrails according to the old policy)
Number of subjects: 0
Study: 12940872

Group type: EXPERIMENTAL
Intervention: Sibutramine, 10 mg once daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11885173

Group type: EXPERIMENTAL
Intervention: Implants placed in the study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stratified analysis of data up to 72 months after implant uncovering
Number of subjects: 0
Study: 8833025

Group type: EXPERIMENTAL
Intervention: Theoretically based, structured experimental treatment program
Number of subjects: 32

Group type: COMPARATOR
Intervention: Relatively unstructured comparison intervention
Number of subjects: 32
Study: 1467099

Group type: EXPERIMENTAL
Intervention: Alfentanil loading dose of 85 micrograms kg‐1 and infusion of 65 micrograms kg‐1 h‐1
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Alfentanil loading dose of 65 micrograms kg‐1 and infusion of 50 micrograms kg‐1 h‐1
Number of subjects: 59
Study: 6205337

Group type: EXPERIMENTAL
Intervention: Cis-dichlorodiammineplatinum(II) (cis-DDP) 33 mg/kg i.v. day 1 and Bleomycin (BLM) 15 mg/m2 i.v. continuously day 2-6 (arm A)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Methotrexate (MTX) 30 mg/m2 i.v. day 1 + 6 and Vindesine (VDS) 3 mg/m2 day 2 + 7 (arm B)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Chemotherapy (both arms combined)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Surgery +/− radiotherapy (in not pretreated patients)
Number of subjects: 79
Study: 31400105

Group type: EXPERIMENTAL
Intervention: App-based parenting education including unintentional injury prevention
Number of subjects: 1980

Group type: COMPARATOR
Intervention: App-based parenting education excluding unintentional injury prevention
Number of subjects: 1980
Study: 29659797

Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg b.i.d., reduced to 2.5 mg b.i.d. if applicable)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Heparin/Vitamin K Antagonist (VKA)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 1500
Study: 27282597

Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 4046

Group type: COMPARATOR
Intervention: Coronary Artery Bypass Graft (CABG)
Number of subjects: 4046
Study: 23336612

Group type: EXPERIMENTAL
Intervention: Typical training and written guidance
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Training, written guidance, and TIM tubes
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Typical training and TIM tubes
Number of subjects: 62

Group type: COMPARATOR
Intervention: Written guidance only
Number of subjects: 62
Study: 21908169

Group type: EXPERIMENTAL
Intervention: Patient-matched instrument system for total knee arthroplasty (Visionaire; Smith & Nephew, Inc, Memphis, Tenn) (VIS)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard TKA surgical instrumentation (STD)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Patient-matched instrument system for total knee arthroplasty (VIS)
Number of subjects: 29
Study: 20106358

Group type: EXPERIMENTAL
Intervention: Radial artery (n = 198)
Number of subjects: 719

Group type: COMPARATOR
Intervention: Right internal thoracic artery (n = 196)
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Radial artery (n = 113)
Number of subjects: 719

Group type: COMPARATOR
Intervention: Saphenous vein (n = 112)
Number of subjects: 719
Study: 17286868

Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 70/30 (BIAsp 70/30)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Glargine (Glar)
Number of subjects: 233
Study: 15643230

Group type: EXPERIMENTAL
Intervention: 160 mg Serenoa repens (SR) orally twice daily for 3 months
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no treatment for 3 weeks before surgery)
Number of subjects: 29
Study: 12217676

Group type: EXPERIMENTAL
Intervention: Automated percutaneous discectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional discectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percutaneous discectomy
Number of subjects: 0
Study: 10972952

Group type: EXPERIMENTAL
Intervention: 60 Hz magnetic fields at a resultant flux density of 28.3 microT
Number of subjects: 24

Group type: COMPARATOR
Intervention: Previous studies with intermittent exposure to 60 Hz magnetic fields
Number of subjects: 24
Study: 8997576

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin ophthalmic solution (0.3%)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Fusidic acid gel (1%)
Number of subjects: 39
Study: 1360665

Group type: EXPERIMENTAL
Intervention: recombinant gp160 vaccine
Number of subjects: 26

Group type: COMPARATOR
Intervention: recombinant hepatitis B vaccine (control)
Number of subjects: 26
Study: 6142907

Group type: EXPERIMENTAL
Intervention: Alprazolam (2 to 6 mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ibuprofen (0.8 to 2.4 g/day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Alprazolam (6.3 mg/day after crossover)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 32
Study: 29480087

Group type: EXPERIMENTAL
Intervention: Running and brisk walking for 30‐45 min twice a week (IND)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Running and brisk walking for 30‐45 min twice a week (GR)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group with no running (C)
Number of subjects: 105
Study: 29373392

Group type: EXPERIMENTAL
Intervention: SystemCHANGE intervention (6 in-person, standardized group sessions focusing on improving lifestyle behaviors)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control condition (general advice on AHA diet and exercise guidelines)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: SystemCHANGE intervention
Number of subjects: 107
Study: 27687353

Group type: EXPERIMENTAL
Intervention: Pectoralis-serratus interfascial plane block (PS group, n=32)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Thoracic paravertebral block (PV group, n=32)
Number of subjects: 64
Study: 25560349

Group type: EXPERIMENTAL
Intervention: Aloe vera gel dressing
Number of subjects: 90

Group type: COMPARATOR
Intervention: Simple dressing (Control)
Number of subjects: 90
Study: 23103771

Group type: EXPERIMENTAL
Intervention: Internet-based therapy (IT)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Internet-based self-help (IS)
Number of subjects: 136
Study: 20484770

Group type: EXPERIMENTAL
Intervention: Working memory task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatial attention task
Number of subjects: 0
Study: 18360314

Group type: EXPERIMENTAL
Intervention: Prevalent infection at baseline
Number of subjects: 1462

Group type: EXPERIMENTAL
Intervention: Incident infection at follow-up
Number of subjects: 1462
Study: 16166192

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 500-3000 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 16
Study: 12721815

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 43
Study: 10357414

Group type: EXPERIMENTAL
Intervention: Intraoperative examination of axillary sentinel lymph nodes by frozen section examination
Number of subjects: 155

Group type: COMPARATOR
Intervention: Immunocytochemistry
Number of subjects: 155
Study: 8949692

Group type: EXPERIMENTAL
Intervention: Alfentanil 20 micrograms/kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (10 micrograms/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Alfentanil 10 micrograms/kg
Number of subjects: 10
Study: 31959139

Group type: EXPERIMENTAL
Intervention: mHealth intervention (standard-of-care case management plus mHealth intervention)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard-of-care case management (control group)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 600
Study: 29676864

Group type: EXPERIMENTAL
Intervention: Autoinjector (AI)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Prefilled Safety Syringe (SS)
Number of subjects: 80
Study: 27940700

Group type: EXPERIMENTAL
Intervention: FAmily‐CEntered Advance Care Planning (FACE) pACP intervention (1 session per week for 3 sessions)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Active comparator (1, Developmental History; 2, Safety Tips; 3, Nutrition/Exercise)
Number of subjects: 97
Study: 24862172

Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP) therapy
Number of subjects: 24
Study: 22721657

Group type: EXPERIMENTAL
Intervention: XIENCE V stenting
Number of subjects: 8061
Study: 20553667

Group type: EXPERIMENTAL
Intervention: Dyadic relapse prevention (DRP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Individual relapse prevention (IRP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 90
Study: 17644828

Group type: EXPERIMENTAL
Intervention: Benzodiazepine discontinuation programme with group psychotherapy
Number of subjects: 2425

Group type: EXPERIMENTAL
Intervention: Benzodiazepine discontinuation programme without psychotherapy
Number of subjects: 2425

Group type: EXPERIMENTAL
Intervention: Usual care
Number of subjects: 2425

Group type: COMPARATOR
Intervention: Control group (1821 long-term users not participating in the programme)
Number of subjects: 2425

Group type: EXPERIMENTAL
Intervention: Complete discontinuation of benzodiazepines
Number of subjects: 2425
Study: 15859929

Group type: EXPERIMENTAL
Intervention: BT563 (monoclonal antibody against interleukin-2 receptor) for 10 days in kidney transplant recipients
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard regimen (cyclosporin and prednisone) in kidney transplant recipients
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: BT563 (monoclonal antibody against interleukin-2 receptor) for 7 days in heart transplant recipients
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard regimen (cyclosporin, prednisone, and OKT3) in heart transplant recipients
Number of subjects: 120
Study: 12190808

Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (ISB) with 15 ml of ropivacaine (5 mg/ml)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Subacromial bursa block (SUB) with 15 ml of ropivacaine (5 mg/ml)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (PLA) with 15 ml of 0.9% saline
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (ISB)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Subacromial bursa block (SUB)
Number of subjects: 45
Study: 10694933

Group type: EXPERIMENTAL
Intervention: Tiagabine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tiagabine and ethanol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 20
Study: 7666018

Group type: EXPERIMENTAL
Intervention: Written guidelines on the prevention of pressure sores
Number of subjects: 33
Study: 2534373

Group type: EXPERIMENTAL
Intervention: 0.5 mg of ipratropium bromide (IPB) followed by 5 mg of salbutamol sulfate (SAS)
Number of subjects: 34

Group type: COMPARATOR
Intervention: 5 mg of salbutamol sulfate (SAS)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Sequential inhaled SAS after IPB
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Repeated dose of SAS
Number of subjects: 34

Group type: COMPARATOR
Intervention: Double-dose SAS
Number of subjects: 34
Study: 990354

Group type: EXPERIMENTAL
Intervention: Simultaneous footrest vibration and back vibration (A1C1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Simultaneous footrest vibration and back roller (A1C2)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Simultaneous footrest vibration, back vibration and back roller (A1C3)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Footrest vibration alone (A1C4)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Back vibration alone (A2C1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Back roller alone (A2C2)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Simultaneous back vibration and back roller (A2C3)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no vibration/stimulation) (A2C4)
Number of subjects: 48
Study: 31882381

Group type: EXPERIMENTAL
Intervention: Intraoperative optimization of depth of anesthesia targeting BIS values at 50 ± 10
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (standard depth of anesthesia management)
Number of subjects: 82
Study: 31564451

Group type: EXPERIMENTAL
Intervention: HBR + sticker group
Number of subjects: 3616

Group type: EXPERIMENTAL
Intervention: HBR-only group
Number of subjects: 3616

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3616
Study: 26592195

Group type: EXPERIMENTAL
Intervention: Problem-solving bibliotherapy
Number of subjects: 124

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 124
Study: 26276354

Group type: EXPERIMENTAL
Intervention: Tamoxifen + Octreotide LAR (TAM + OCT)
Number of subjects: 1560

Group type: COMPARATOR
Intervention: Tamoxifen (TAM)
Number of subjects: 1560
Study: 23142202

Group type: EXPERIMENTAL
Intervention: PRX302
Number of subjects: 92

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 92
Study: 21720704

Group type: EXPERIMENTAL
Intervention: Chemotherapy + low-dose IL-2 (CT+IL-2)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Chemotherapy (CT)
Number of subjects: 241
Study: 19695392

Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg oral dose on day 1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (on day 1)
Number of subjects: 12
Study: 16427212

Group type: EXPERIMENTAL
Intervention: Pelvic irradiation (RT)
Number of subjects: 277
Study: 14524509

Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique (MET) combined with supervised neuromuscular re‐education and resistance training
Number of subjects: 19

Group type: COMPARATOR
Intervention: Supervised neuromuscular re‐education and resistance training
Number of subjects: 19
Study: 11109647

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 9019177

Group type: EXPERIMENTAL
Intervention: Haemodilution group (6% hydroxyethyl starch 200/0.5, aimed haematocrit of 30%)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Haemodilution group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 1550909

Group type: EXPERIMENTAL
Intervention: Sublingual tablets
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral sustained-release tablets
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oral solution
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sustained-release tablets
Number of subjects: 8
Study: 2408897

Group type: EXPERIMENTAL
Intervention: MOPP
Number of subjects: 53

Group type: COMPARATOR
Intervention: ABVD
Number of subjects: 53
Study: 29745307

Group type: EXPERIMENTAL
Intervention: Dance program, twice a week for 10 weeks
Number of subjects: 20
Study: 27865961

Group type: EXPERIMENTAL
Intervention: Lifetime major depressive disorder (L-MDD)
Number of subjects: 1285

Group type: EXPERIMENTAL
Intervention: Lifetime generalized anxiety disorder (L-GAD)
Number of subjects: 1285
Study: 24923623

Group type: EXPERIMENTAL
Intervention: Online-delivered physical activity intervention (STRIDE website access)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (pedometer only)
Number of subjects: 0
Study: 22377840

Group type: EXPERIMENTAL
Intervention: Preoperative ultrasound followed by surgical repair based on ultrasonographic findings
Number of subjects: 92

Group type: COMPARATOR
Intervention: Clinical diagnosis based on history of trauma and physical examination
Number of subjects: 92